News Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 08/05/2026 pm IST			5-day change	1st Jan Change
5.430 ^HKD	-0.55%		+0.18%	-12.14%

07/05	Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China	MT
07/05	Sino Biopharmaceutical says China CDE accepts new drug application for M701 CD3/Epcam bispecific antibody	RE

All News

Mentions Relevance

07/05	Sino Biopharmaceutical says China CDE accepts new drug application for M701 CD3/Epcam bispecific antibody	RE
07/05	Sino Biopharm Unit's Application for Ascites Drug Accepted in China	MT
07/05	Sino Biopharmaceutical Enrolls First Patient in Cafelkibart Cancer Drug Trial	MT
06/05	Sino Biopharmaceutical's Culmerciclib capsule receives NMPA approval for first-line HR+/HER2- advanced breast cancer in China	RE
06/05	Sino Biopharmaceutical's Breast Cancer Drug Gets Marketing Nod in China	MT
29/04	Sino Biopharmaceutical Limited Announces Board and Committee Changes	CI
28/04	Sino Biopharmaceutical Limited Announces Executive Appointments	CI
28/04	Sino Biopharmaceutical Appoints Chief Medical Officer	MT
28/04	Sino Biopharmaceutical : Xu Xiao, First Secretary of the Secretariat of the Central Committee of the Communist Youth League, Leads Delegation to Inspect Chia Tai Tianqing, Focusing on Innovative Development and Youth Talent Cultivation	PU
20/04	Sino Biopharmaceutical Unit Gets China Nod to Market Cancer Drug	MT
20/04	Sino Biopharmaceutical says Benmelstobart, Anlotinib receive NMPA approval for advanced ASPS in China	RE
20/04	Sino Biopharmaceutical Limited Announces Approval of Benmelstobart in Combination with Anlotinib for Treatment of Alveolar Soft Part Sarcoma	CI
15/04	Sino Biopharmaceutical Unit Enrolls First Patient in Gastric Cancer Drug Trial	MT
10/04	Sino Biopharmaceutical Enrolls First Patient in Heart Drug Study	MT
10/04	Sino Biopharmaceutical Limited Announces Completion of Enrollment of First Patient in Phase II Clinical Trial of Kylo-11 LPA SiRNA in the United States	CI
10/04	Sino Biopharmaceutical : Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11	PU
09/04	Sino Biopharmaceutical says naldemedine approved for marketing in Greater Bay Area	RE
09/04	Sino Biopharm Gets Launch Nod for Opioid-Induced Constipation Drug from Guangdong Regulator	MT
09/04	Sino Biopharmaceutical Receives US Regulatory Nod to Begin Trials of Anti Tumor Drug	MT
09/04	Sino Biopharmaceutical says application for clinical trial on TQB3205 "Pan-Kras inhibitor" approved by FDA	RE
27/03	Nomura Adjusts Sino Biopharmaceutical's Price Target to HK$8.67 From HK$9.17, Keeps at Buy	MT
27/03	Sino Biopharmaceutical Limited commences an Equity Buyback Plan for 1,876,071,723 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2025.	CI
27/03	Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion	PU
26/03	Sino Biopharma's Profit Slips in 2025; Dividend Declared	MT
26/03	Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2025, Payable on 20 July 2026	CI